Caffeine and Progression of Parkinson Disease: A Deleterious Interaction With Creatine
Simon DK, Wu C, Tilley BC, Wills AM, Aminoff MJ, Bainbridge J, Hauser RA, Schneider JS, Sharma S, Singer C, Tanner CM, Truong D, Wong PS
Clinical neuropharmacology · 21 citations
How it was studied
- Design
- Randomized controlled trial (indexed by PubMed)
- Studied in
- People
- Main outcome
- Health markers and function
Who paid for it
- Funding
- Independent funding
- Government
- National Institute of Neurological Disorders and Stroke
- Government
- National Center for Research Resources
- Government
- NCRR NIH HHS
- Government
- NINDS NIH HHS
- Grants
- National Center for Research Resources (UL1 RR 025758); National Institute of Neurological Disorders and Stroke (U10 NS044482)
Based on 4 listed funder(s).
Publication
- Published
- 2015-09-01 · Clin Neuropharmacol · vol. 38 · issue 5 · pp. 163–169
- Publisher
- Lippincott Williams & Wilkins
- Cited
- 28 citations · more than 92% of similar papers · 3.6× the field average
- Impact
- Top 10% most cited in its field
- References
- 21 works
- Access
- Open access (repository copy)
- Research areas
- Coffee research and impacts · Parkinson's Disease Mechanisms and Treatments · Folate and B Vitamins Research
- Keywords
- Caffeine, Medicine, Parkinson's disease, Disease, Neuroscience, Psychology, Internal medicine
- MeSH
- humans, parkinson disease, disease progression, creatine, caffeine, central nervous system stimulants, drug interactions, middle aged, female, male
13 authors
From US, SG
- David K. Simon · correspondingBeth Israel Deaconess Medical Center; Harvard University; University of Rochester Medicine; University of Colorado Anschutz
- Cai WuUniversity of Miami; The University of Texas Health Science Center at Houston
- Barbara C. TilleyUniversity of Miami; The University of Texas Health Science Center at Houston
- Anne-Marie A. WillsSan Francisco VA Medical Center; Harvard University; Massachusetts General Hospital
- Michael J. AminoffUniversity of California, San Francisco; Parkinson's and Movement Disorder Institute
- Jacquelyn L. BainbridgeSingapore General Hospital; University of Colorado Anschutz; University of Montana
Abstract
Objective
Increased caffeine intake is associated with a lower risk of Parkinson disease (PD) and is neuroprotective in mouse models of PD. However, in a previous study, an exploratory analysis suggested that, in patients taking creatine, caffeine intake was associated with a faster rate of progression. In the current study, we investigated the association of caffeine with the rate of progression of PD and the interaction of this association with creatine intake.
Methods
Data were analyzed from a large phase 3 placebo-controlled clinical study of creatine as a potentially disease-modifying agent in PD. Subjects were recruited for this study from 45 movement disorders centers across the United States and Canada. A total of 1741 subjects with PD participated in the primary clinical study, and caffeine intake data were available for 1549 of these subjects. The association of caffeine intake with rate of progression of PD as measured by the change in the total Unified Parkinson Disease Rating Scale score and the interaction of this association with creatine intake were assessed.
Results
Caffeine intake was not associated with the rate of progression of PD in the main analysis, but higher caffeine intake was associated with significantly faster progression among subjects taking creatine.
Conclusions
This is the largest and longest study conducted to date that addresses the association of caffeine with the rate of progression of PD. These data indicate a potentially deleterious interaction between caffeine and creatine with respect to the rate of progression of PD.
Abstract via Europe PMC. Copyright remains with the authors or publisher.
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.